Glucosamine is an important part of the treatment strategy for osteoarthritis, but its effectiveness is still controversial. To explain the efficacy differences of glucosamine, in this study the investigators detect the concentration of glucosamine in the plasma and synovial fluid, some effect indexes such as inflammatory markers and gene polymorphism of glucosamine transporters. On the one hand, the investigators compare the plasma peak and gluten glucosamine concentration and the concentration in synovial fluid among participants to observe the individual differences of glucosamine exposure in vivo. On the other hand, the investigators investigate the correlation between drug concentrations, effect index and gene polymorphism. The hypothesis is that glucosamine exposure in vivo has individual differences and gene polymorphism can explain this differences.
Study Type
OBSERVATIONAL
Enrollment
400
Patients taking glucosamine sulfate 1500mg every day for at least four days.
Drug concentration in plasma
Drug concentration is measured by HPLC-MS/MS
Time frame: Fasting venous blood before the first administration
Drug concentration in plasma
Drug concentration is measured by HPLC-MS/MS
Time frame: 3 hours after the third administration
Drug concentration in plasma
Drug concentration is measured by HPLC-MS/MS
Time frame: 9 hours after the third administration
Drug concentration in plasma
Drug concentration is measured by HPLC-MS/MS
Time frame: Fasting venous blood before the fourth administration
Drug concentration in plasma
Drug concentration is measured by HPLC-MS/MS
Time frame: Venous blood during the operation of total knee arthroplasty
Drug concentration in synovial fluid
Drug concentration is measured by HPLC-MS/MS
Time frame: During the operation of total knee arthroplasty
Inflammatory markers in plasma
Leptin
Time frame: Fasting venous blood before the first administration
Inflammatory markers in plasma
Leptin
Time frame: 3 hours after the third administration
Inflammatory markers in plasma
Leptin
Time frame: 9 hours after the third administration
Inflammatory markers in plasma
Leptin
Time frame: Fasting venous blood before the fourth administration
Inflammatory markers in plasma
Leptin
Time frame: During the operation of total knee arthroplasty
Inflammatory markers in plasma
IL-1β
Time frame: Fasting venous blood before the first administration
Inflammatory markers in plasma
IL-1β
Time frame: 3 hours after the third administration
Inflammatory markers in plasma
IL-1β
Time frame: 9 hours after the third administration
Inflammatory markers in plasma
IL-1β
Time frame: Fasting venous blood before the fourth administration
Inflammatory markers in plasma
IL-1β
Time frame: During the operation of total knee arthroplasty
Inflammatory markers in plasma
COX-2
Time frame: Fasting venous blood before the first administration
Inflammatory markers in plasma
COX-2
Time frame: 3 hours after the third administration
Inflammatory markers in plasma
COX-2
Time frame: 9 hours after the third administration
Inflammatory markers in plasma
COX-2
Time frame: Fasting venous blood before the fourth administration
Inflammatory markers in plasma
COX-2
Time frame: During the operation of total knee arthroplasty
Inflammatory markers in plasma
IL-6
Time frame: Fasting venous blood before the first administration
Inflammatory markers in plasma
IL-6
Time frame: 3 hours after the third administration
Inflammatory markers in plasma
IL-6
Time frame: 9 hours after the third administration
Inflammatory markers in plasma
IL-6
Time frame: Fasting venous blood before the fourth administration
Inflammatory markers in plasma
IL-6
Time frame: During the operation of total knee arthroplasty
Inflammatory markers in plasma
TNFα
Time frame: Fasting venous blood before the first administration
Inflammatory markers in plasma
TNFα
Time frame: 3 hours after the third administration
Inflammatory markers in plasma
TNFα
Time frame: 9 hours after the third administration
Inflammatory markers in plasma
TNFα
Time frame: Fasting venous blood before the fourth administration
Inflammatory markers in plasma
TNFα
Time frame: During the operation of total knee arthroplasty
Inflammatory markers in plasma
MMP-3
Time frame: Fasting venous blood before the first administration
Inflammatory markers in plasma
MMP-3
Time frame: 3 hours after the third administration
Inflammatory markers in plasma
MMP-3
Time frame: 9 hours after the third administration
Inflammatory markers in plasma
MMP-3
Time frame: Fasting venous blood before the fourth administration
Inflammatory markers in plasma
MMP-3
Time frame: During the operation of total knee arthroplasty
Inflammatory markers in plasma
ADAM-TS5
Time frame: Fasting venous blood before the first administration
Inflammatory markers in plasma
ADAM-TS5
Time frame: 3 hours after the third administration
Inflammatory markers in plasma
ADAM-TS5
Time frame: 9 hours after the third administration
Inflammatory markers in plasma
ADAM-TS5
Time frame: Fasting venous blood before the fourth administration
Inflammatory markers in plasma
ADAM-TS5
Time frame: During the operation of total knee arthroplasty
Inflammatory markers in synovial fluid
Leptin
Time frame: During the operation of total knee arthroplasty
Inflammatory markers in synovial fluid
IL-1β
Time frame: During the operation of total knee arthroplasty
Inflammatory markers in synovial fluid
COX-2
Time frame: During the operation of total knee arthroplasty
Inflammatory markers in synovial fluid
IL-6
Time frame: During the operation of total knee arthroplasty
Inflammatory markers in synovial fluid
TNFα
Time frame: During the operation of total knee arthroplasty
Inflammatory markers in synovial fluid
MMP-3
Time frame: During the operation of total knee arthroplasty
Inflammatory markers in synovial fluid
ADAM-TS5
Time frame: During the operation of total knee arthroplasty
Gene polymorphism
Gene polymorphisms of glucosamine transporters in vivo
Time frame: Fasting venous blood before the first administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.